Exchange: NASDAQ·Updated 04:30 PM EST

LRMR News

News
all
press releases
Larimar Therapeutics (NASDAQ:LRMR) Stock Breaks Above 50-Day Moving Average - Here's What Happened
Larimar Therapeutics (NASDAQ:LRMR) Share Price Crosses Above 50-Day Moving Average - Should You Sell...
MarketBeat
Larimar Therapeutics (NASDAQ:LRMR) Stock Breaks Above 50-Day Moving Average - Here's What Happened
Larimar Therapeutics (NASDAQ:LRMR) Share Price Crosses Above 50-Day Moving Average - Should You Sell...
MarketBeat
More News
The heavy selling pressure might have exhausted for Larimar (LRMR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
Zacks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR PR Newswire NEW YORK, July 23, 2026 NEW YORK, July 23, 2026...
PR Newswire
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy...
Yahoo! Finance: News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR PR Newswire NEW YORK, July 9, 2026 NEW YORK, July 9, 2026...
PR Newswire
The shares were acquired in multiple transactions at prices ranging from $3.33 to $3.35 per share.
Stocktwits
H.C. Wainwright initiated coverage of Larimar with a ‘Buy’ rating and a $10 price target on Thursday.
Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR PR Newswire NEW YORK, July 1, 2026 NEW YORK, July 1, 2026...
PR Newswire
Larimar Therapeutics Inc (LRMR) submits first module of Biologics License Application for investigational treatment for Friedreich's ataxia, with FDA support and positive long-term data showing durable safety profile and clinical improvements compared to natural history data.read more...
Benzinga

Advertisement|Remove ads.